摘要
2型糖尿病(type 2 diabetes mellitus,T2DM)是严重影响人类身体健康和生活质量的慢性疾病。研究发现其与肠道微生物的组成密切相关。随着目前肠道微生物的作用受到广泛关注,我们对2型糖尿病患者肠道菌群的变化有了更深入了解,许多功能强大的有益菌如阿克曼氏菌、柔嫩梭菌被发现,并发现由多种厌氧菌产生的不同短链脂肪酸对2型糖尿病患者的有益影响。补充有益菌和摄入益生菌制剂等通过调节肠道微生物群可能对预防和治疗2型糖尿病有效,但由于肠道微生物的复杂性和益生菌的局限性,需要进一步研究来评估益生菌的最佳剂量反应效应,并应用多组学方法提高基于微生物干预的个性化治疗,缓解和治疗2型糖尿病等代谢疾病。
Type 2 diabetes mellitus（T2DM） is the chronic illness that seriously impacts on people＇s health and quality of life. Studies found that T2DM was associated with the composition of gut microbiota. With the role of gut microbes received widespread attention, we have a better understanding of the changes of gut microbiota in patients with T2DM. Many powerful beneficial bacteria such as Akkermansia muciniphila and Clostridium leptum have been discovered. And it is also found that different short chain fatty acids produced by a variety of anaerobic bacteria can be beneficial to T2DM patients. Supplementation of beneficial bacteria and intake of complex-probiotic-preparation may be effective towards prevention and treatment of T2DM by regulating the gut microbiota community. But due to the complexity of gut microbiota and the limitations of probiotics, further research is needed to assess the optimal dose response effect of probiotics and to apply a multi-omics approach to improve individualized treatment based on microbial intervention to alleviate and treat metabolic diseases such as T2DM.
作者
李昱
孔祥阳
LI Yu;KONG Xiangyang(Genetics and Pharmacogenomics Laboratory,Medical School,Kunming University of Science and Technology,Kunming 650500,China)
出处
《生命的化学》
CAS
CSCD
2018年第4期507-514,共8页
Chemistry of Life
